Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Glucagon for hypoglycaemia treatment in type 1 diabetes

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. EDUCATION PROGRAMMES FOR PERSONS WITH TYPE 1 DIABETES USING AN INSULIN PUMP: A SYSTEMATIC REVIEW

    Research output: Contribution to journalReviewResearchpeer-review

  2. Treatment of modifiable risk factors for foot ulceration in persons with diabetes: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Glucose homeostasis in statin users-The LIFESTAT study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Oral insulin does not alter gut microbiota composition of NOD mice

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

To achieve strict glycaemic control and avoid chronic diabetes complications, individuals with type 1 diabetes (T1D) are recommended to follow an intensive insulin regimen. However, the risk and fear of hypoglycaemia often prevent individuals from achieving the treatment goals. Apart from early insulin suspension in insulin pump users, carbohydrate ingestion is the only option for preventing and treating non-severe hypoglycaemic events. These rescue treatments may give extra calories and cause overweight. As an alternative, the use of low-dose glucagon to counter hypoglycaemia has been proposed as a tool to raise glucose concentrations without adding extra calories. Previously, the commercially available glucagon formulations required reconstitution from powder to a solution before being injected subcutaneously or intramuscularly-making it practical only for treating severe hypoglycaemia. Several companies have developed more stable formulations that do not require the time-consuming reconstitution process before use. As well as treating severe hypoglycaemia, non-severe and impending hypoglycaemia can also be treated with lower doses of glucagon. Once available, low-dose glucagon can be either delivered manually, as an injection, or automatically, by an infusion pump. This review focuses on the role and perspectives of using glucagon to treat and prevent hypoglycaemia in T1D.

Original languageEnglish
JournalDiabetes - Metabolism: Research and Reviews (Print Edition)
Pages (from-to)e3409
ISSN1520-7552
DOIs
Publication statusE-pub ahead of print - 25 Sep 2020

    Research areas

  • carbohydrate rescue, closed-loop, glucagon, glucose control, hypoglycaemia, type 1 diabetes

ID: 61262406